Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBL-514 for Reducing Abdominal Subcutaneous Fat
NCT07608757Phase 2Not yet recruiting
- Sponsor
- Caliway Biopharmaceuticals
- Start
- Feb 2027
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
A Phase 2 trial of CBL-514 in subcutaneous fat, sponsored by Caliway Biopharmaceuticals. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
CBL-514
03
Conditions
subcutaneous fat
Beyond the preview
Go deeper on NCT07608757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07608757.